Lexaria Bioscience (LEXX) Form 4 Lexaria Bioscience / CHRISTOPHER BUNKA ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

BUNKA CHRISTOPHER

(Last) (First) (Middle)

1924 BIRKDALE AVE

(Street)

KELOWNA A1 V1P1R7

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexaria Bioscience Corp. [ LEXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
04/26/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
common shares								273,543	D
common shares								254,412	I	Private Holding Company

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	$10.5							05/06/2020	05/06/2025	Common Shares	6,667		6,667	I	Private Holding Company
Stock Options	$3(1)							04/26/2021	04/26/2026	Common Shares	26,000		32,667	D
Stock Options	$3(2)							06/08/2021	06/08/2026	Common Shares	23,334		56,001	D
Stock Options	$3(3)							09/01/2021	09/01/2026	Common Shares	15,000		71,001	D
Stock Options	$2.91							08/29/2022	08/29/2027	Common Shares	30,000		101,001	D
Stock Options	$1.15							10/26/2023	10/26/2028	Common Shares	30,000		131,001	D
Stock Options	$2.36	04/26/2024		A		49,500		04/26/2024	04/26/2029	Common Shares	49,500	$0	180,501	D

Explanation of Responses:

1. Repriced from $5.83 pursuant to shareholder approval received on May 9, 2023

2. Repriced from $7.08 pursuant to shareholder approval received on May 9, 2023

3. Repriced from $6.23 pursuant to shareholder approval received on May 9, 2023

	/Chris Bunka/	05/10/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.